Wang M, Liang H, Wang W, et al. - Via this meta‐analysis, researchers determined the rate of immune‐related adverse events (irAEs) with a PD‐(L)1 inhibitor plus chemotherapy (I+C) vs a PD‐(L)1 inhibitor alone (I) as a first‐line treatment for advanced non–small cell lung cancer (NSCLC). In addition, they examined the indirect relative risk (RR) of I+C vs I. Findings suggest that a combination of I+C for the first‐line treatment of NSCLC resulted in reduction in the rates of most irAEs, such as pneumonitis and endocrine and skin reactions, as well as the overall rate, vs a PD‐(L)1 inhibitor alone.